|Articles|September 20, 2017

Lack of Trust Less of a Barrier to Clinical Trial Participation

In a recent public opinion survey commissioned by Research!America, the percentage of respondents including African-Americans, Hispanics, Asians and non-Hispanic whites who cited ‘lack of trust’ as a reason why they do not participate in clinical trials declined, thus showing that most of them feel other factors contribute to low participation rates.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© putilov_denis - © putilov_denis - stock.adobe.com

October 5th, 2026

Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?

Mixed FSP and FSO models are gaining ground as sponsors seek agility and resource flexibility, but the oversight infrastructure, audit trails, and accountability structures needed to run them well and survive regulatory inspection are consistently lagging behind the model itself.

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

October 5th, 2026

FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine

A new request for information asks for comments on dose selection, safety monitoring, eligibility criteria, and oversight approaches to support the responsible development of ibogaine drug products.

October 5th, 2026

ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination

In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.

October 2nd, 2026

Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where

Hierarchical composite endpoints analyzed through pairwise comparisons more accurately reflect multifaceted treatment benefit than time-to-first-event composites, but transparent outcome prioritization, patient involvement in ranking, and reporting of Net Treatment Benefit remain underutilized despite their importance to interpretation.

October 2nd, 2026

What ClinOps Professionals Just Starting With AI Should Keep Top of Mind

In this video interview, Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey—making the case that the tools are more accessible than many assume and that waiting to start is a competitive risk in itself.

October 2nd, 2026

ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment

In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.

© Tada Images - © Tada Images - stock.adobe.com

October 1st, 2026

HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure

The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.

October 1st, 2026

What an AI-Informed Approach Means for How Sponsors Think About Risk

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.